China Traditional Chinese Medicine Holdings Co (STU:WSG) Debt-to-EBITDA : N/A (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:WSG China Traditional Chinese Medicine Holdings Co Ltd STU:WSG
50 GF Score
Price €0.14
GF Value €0.27
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is China Traditional Chinese Medicine Holdings Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

China Traditional Chinese Medicine Holdings Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €272 Mil. China Traditional Chinese Medicine Holdings Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €25 Mil. China Traditional Chinese Medicine Holdings Co's annualized EBITDA for the quarter that ended in Dec. 2025 was €78 Mil. China Traditional Chinese Medicine Holdings Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 was 3.81.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for China Traditional Chinese Medicine Holdings Co's Debt-to-EBITDA or its related term are showing as below:

STU:WSG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.4   Med: 2.29   Max: 2.79
Current: -1.4

During the past 13 years, the highest Debt-to-EBITDA Ratio of China Traditional Chinese Medicine Holdings Co was 2.79. The lowest was -1.40. And the median was 2.29.

STU:WSG's Debt-to-EBITDA is ranked worse than
100% of 678 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs STU:WSG: -1.40

China Traditional Chinese Medicine Holdings Co  (STU:WSG) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

China Traditional Chinese Medicine Holdings Co Debt-to-EBITDA Related Terms

China Traditional Chinese Medicine Holdings Co Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for China Traditional Chinese Medicine Holdings Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Traditional Chinese Medicine Holdings Co Debt-to-EBITDA Chart

China Traditional Chinese Medicine Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.49 2.24 1.99 2.83 2.86

China Traditional Chinese Medicine Holdings Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

STU:WSG vs ZTS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Traditional Chinese Medicine Holdings Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Traditional Chinese Medicine Holdings Co Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Traditional Chinese Medicine Holdings Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where China Traditional Chinese Medicine Holdings Co's Debt-to-EBITDA falls into.


STU:WSG
50GF Score
China Traditional Chinese Medicine Holdings Co Ltd STU:WSG
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Traditional Chinese Medicine Holdings Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

China Traditional Chinese Medicine Holdings Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(272.13813270293 + 25.31279493171) / 106.27145727387
=2.80

China Traditional Chinese Medicine Holdings Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(272.13813270293 + 25.31279493171) / 78.073448943504
=3.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.

Is China Traditional Chinese Medicine Holdings Co (STU:WSG) Overvalued in 2026?

Based on GuruFocus' analysis, China Traditional Chinese Medicine Holdings Co stock appears to be undervalued. The current stock price of €0.14 is trading 48.9% below its estimated GF Value™ of €0.27. GuruFocus considers China Traditional Chinese Medicine Holdings Co to be Possible Value Trap.

Key valuation signals for STU:WSG:

  • Debt-to-EBITDA: N/A
  • GF Value™: €0.27 vs. price of €0.14 (48.9% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the STU:WSG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Traditional Chinese Medicine Holdings Co Business Description

Other Exchanges CHIZF:USA00570:Hong Kong
Address 288 Hennessy Road, Room 1601, Emperor Group Centre, Wanchai, Hong Kong, HKG
China Traditional Chinese Medicine Holdings Co Ltd is engaged in the Chinese healthcare sector. The company functions through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. It generates maximum revenue from the Yifang segment which mainly engages in the manufacture and sales of concentrated TCM granules (CTCMG), TCM healthcare products, and TCM decoction pieces under the Yi Fang brand. The majority of the revenue of the Yi Fang segment is derived from the sales of CTCMG. Geographically, it derives a majority of its revenue from Mainland China, and also has its presence in Hong Kong and Other countries.
50GF Score

Get the complete analysis for STU:WSG

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.27
GF Value